Investigational Agents in Ulcerative Colitis: IL-12 and IL-23 Inhibitors

Update: 2019-04-29

Description

Investigational Agents in Ulcerative Colitis: IL-12 and IL-23 InhibitorsInflammatory bowel disease, which includes ulcerative colitis (UC) and Crohn’s disease, affects an estimated 3 million adults in the United States. Although numerous therapies are available for the treatment of moderate to severe UC, many patients still suffer poor quality of life and suboptimal outcomes. Therefore, safer and more effective UC therapies are needed.

In this CME podcast activity, Dr. Peter Higgins and Dr. David Rubin will discuss investigational interleukin-12 and interleukin-23 inhibitors for treating UC.

For the transcript of this podcast, click here.

To obtain CME credit, click here

Comments

In Channel

Pearls From the Pros on IBD Management: Anti-Integrin and S1P Receptor Modulation in IBD Practice With Drs. David Rubin and Maria Abreu

2022-01-0624:58

Pearls From the Pros on IBD Management: JAK Inhibition in IBD Practice With Drs. David Rubin and Millie Long

2022-01-0621:07

Pearls From the Pros on IBD Management: Anti-IL-12/23 in IBD Practice With Drs. David Rubin and Bruce Sands

2022-01-0616:34

Pearls From the Pros on IBD Management: Anti-TNF Therapy in IBD Practice With Drs. David Rubin and Stephen Hanauer

2022-01-0622:22

Immunogenicity of Current IBD Biologics With Drs. Edward Loftus and Marla Dubinsky

2021-08-1813:25

Extraintestinal Manifestations of IBD With Drs. Edward Loftus and Miguel Regueiro

2021-08-1810:36

Biologics for IBD – Monotherapy Versus Combination Approaches With Drs. Edward Loftus and Marla Dubinsky

2021-08-1814:30

New Insights on Treat to Target in Moderate to Severe IBD With Drs. Edward Loftus and Miguel Regueiro

2021-08-1815:19

Efficacy and Safety of Anti-interleukin (IL) 23 and Janus Kinase (JAK) Inhibitors with Drs. William J. Sandborn and Jessica R. Allegretti

2021-03-1616:48

Efficacy and Safety of Anti-integrin and Sphingosine-1-Phosphate (S1P)-1 Receptor Modulators with Drs. Bruce E. Sands and William J. Sandborn

2021-03-1615:37

Mechanisms of Action of New Classes of Agents for Moderate to Severe Crohn’s Disease with Drs. William J. Sandborn and Bruce E. Sands

2021-03-1619:34

Inequities in IBD Research, With Drs. Miguel Regueiro and Kofi Clarke

2025-07-0120:43

Overcoming Obstacles to Equitable, Evidence-Based IBD Care, With Dr. Millie Long, Dr. Sandra Quezada, and Ms. Tina Aswani-Omprakash

2025-07-0132:05

Addressing Barriers to Equitable Inclusion in Clinical Trials, With Dr. Miguel Regueiro, Dr. Neilanjan Nandi, and Ms. Tina Aswani-Omprakash

2025-06-3025:34

Racial, Ethnic, and Socioeconomic Disparities in IBD Care With Drs. Millie Long and Edward Barnes

2025-06-3019:26

Diet and Targeted Therapy With Drs. Dellon and Hirano

2023-05-1930:25

Steroids and PPIs in the Treatment of EoE With Drs. Dellon and Beveridge

2023-05-1922:48

Differential Diagnosis of EoE With Drs. Dellon and Chehade

2023-05-1926:11

Investigational Agents in Ulcerative Colitis: IL-12 and IL-23 Inhibitors

2019-04-2912:25

Investigational Agents in Ulcerative Colitis: JAK Inhibitors and S1P Receptor Modulators

2019-04-2909:12

00:00

Investigational Agents in Ulcerative Colitis: IL-12 and IL-23 Inhibitors

Peter Higgins, MD and David Rubin, MD - Vindico Medical Educaition

#box-pro-ellipsis-175758462631712{-webkit-line-clamp:2;}Investigational Agents in Ulcerative Colitis: IL-12 and IL-23 Inhibitors

Investigational Agents in Ulcerative Colitis: IL-12 and IL-23 Inhibitors

Peter Higgins, MD and David Rubin, MD - Vindico Medical Educaition

Investigational Agents in Ulcerative Colitis: IL-12 and IL-23 Inhibitors